Skip to Content
Merck
All Photos(1)

Key Documents

H0100100

Haloperidol decanoate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Decanoic acid 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl ester

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C31H41ClFNO3
CAS Number:
Molecular Weight:
530.11
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

haloperidol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

InChI key

GUTXTARXLVFHDK-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Haloperidol decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lucilene Cardoso et al.
Revista da Escola de Enfermagem da U S P, 43(1), 161-167 (2009-05-15)
Non-compliance with drug-based treatment is a complex and universal phenomenon that develops gradually during psychiatric treatments, and is related to disease aggravation. The purpose of this study was to describe the profile of using a given medication in the clientele
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Joshua T Kantrowitz et al.
Journal of clinical psychopharmacology, 27(5), 525-526 (2007-09-18)
Delphine Charvin et al.
Neurobiology of disease, 29(1), 22-29 (2007-10-02)
Huntington's disease (HD) results from an abnormal polyglutamine extension in the N-terminal region of the huntingtin protein. This mutation causes preferential degeneration of striatal projection neurons. We previously demonstrated, in vitro, that dopaminergic D2 receptor stimulation acted synergistically with mutated
Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Raymond A Lorenz et al.
Journal of clinical psychopharmacology, 27(5), 524-525 (2007-09-18)
Nancy C Brahm et al.
Journal of pharmacy practice, 24(6), 561-563 (2011-11-04)
Intramuscular (IM) injection is a commonly used administration route for a variety of medications. Determining the optimum needle length for administration of IM formulations based on individual patient variables has not been extensively reported in patients receiving antipsychotic medication via

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service